Source: Annual Congress 2002 - Lung cancer: clinical characteristics and prognosis
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Ediger, E. Kunt Uzaslan, M. Karadag, E. Gurdal Yuksel, E. Ege, N. Ozyardimci, O. Gozu, Z. Yavuz, F. Coskun (Bursa, Turkey). Evaluation of serum tumour markers in the lung cancer patients. Eur Respir J 2002; 20: Suppl. 38, 1718

Member's Comments

No comment yet.

Related content which might interest you: Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Tumor markers in bronchial secretions and serum in patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 The evaluation of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 323s Year: 2005 Contribution of tumor markers to pretreatment staging of operable lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 360s Year: 2003 Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Markers of angiogenesis in serum are correlating with disease progress in lung cancer Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006